Dr. Stephen Ansell

Fighting lymphoma: Treatment options include alternatives to chemotherapy

Dr. Stephen Ansell discusses research to develop new lymphoma therapies and the currently available nonchemotherapy treatment options.

Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma

Researchers found that the addition of brentuximab vedotin to standard chemotherapy improves overall survival in people with Hodgkin Lymphoma.

The American Society of Hematology recognizes Stephen Ansell, M.D., for lymphoma research

The American Society of Hematology (ASH) recognized Mayo Clinic hematologist Stephen Ansell, M.D., with the highly distinguished Ernest Beutler Lecture and Prize in recognition of his significant contributions to the field of lymphoma research.